Hearscape
← Companies
Organization

Regeneron Pharmaceuticals

Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.

All ProgramsTherapeuticsDevices
Open filtered programs
Programs
5
linked to organization
Strong Evidence
1
2 status confirmed
Details Checked
5
0 open data checks
Company / Institution Links
4 / 1
industry vs non-industry records
Competitive Density
7
Pipeline Velocity
6
Completion Signal
40

Programs by Stage

Preclinical2
Early Phase 11
Phase 11
Approved1

Trial / Program Status

Approved1
Completed1
Unknown3

Modality Mix

Gene Therapy3
Biologic1
Drug Delivery1

Indication Coverage

Hearing Loss5
Sensorineural Hearing Loss4
Genetic Hearing Loss3
Auditory Neuropathy1
Autoimmune Inner Ear Disease1
Cisplatin-Induced Hearing Loss1
OTOF-Related Hearing Loss1

Program Types

Therapeutic5

Population Tags

adult3
congenital3
genetic3
pediatric3
bilateral2
pre-lingual2
autoimmune-inner-ear-disease1
cisplatin-ototoxicity1
older-adult1
otof-dfnb91

Strong-Evidence Records

1 records
Otarmeni by Regeneron
Strong evidence
Gene TherapyApprovedApproved

Dual-AAV intracochlear gene replacement delivers functional OTOF to cochlear inner hair cells to restore otoferlin-mediated auditory signaling.

Checked Records With Caveats

5 checked · 0 open checks
DB-020 by Regeneron and Decibel
Status confirmed
Drug DeliveryPhase 1Completed

Locally delivered thiosulfate formulation is injected through the eardrum to inactivate cisplatin in the cochlea while minimizing systemic tumor-protection risk.

AAV.103 by Regeneron
Details checked
Gene TherapyPreclinicalUnknown

Preclinical AAV-based gene therapy program for GJB2-related congenital monogenic hearing loss; specific public technical details remain limited.

Data checks: current-status-not-publicly-disclosed, route-not-publicly-disclosed
AAV.104 by Regeneron
Details checked
Gene TherapyPreclinicalUnknown

Preclinical AAV-based gene therapy program for STRC-related congenital monogenic hearing loss; specific public technical details remain limited.

Data checks: current-status-not-publicly-disclosed, route-not-publicly-disclosed
Investigator-sponsored rilonacept study for autoimmune neurosensory hearing loss
Details checked
BiologicEarly Phase 1Unknown

Subcutaneous interleukin-1 blocker/cytokine trap. The Arcalyst label describes rilonacept as binding IL-1 alpha and IL-1 beta as a soluble decoy receptor, while the hearing study tested whether IL-1 blockade could improve autoimmune neurosensory hearing loss.

Data checks: investigator-sponsored-not-company-pipeline, registry-only-current-status